Cargando…
High Immunoreactivity of DUOX2 Is Associated With Poor Response to Preoperative Chemoradiation Therapy and Worse Prognosis in Rectal Cancers
Purpose: Colorectal cancer is the third most common cancer and also the fourth most common cause of cancer mortality worldwide. For rectal cancer, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by radical proctectomy is gold standard treatment for patients with stage II/III rectal cancer....
Autores principales: | Lin, Shih-Chun, Chang, I-Wei, Hsieh, Pei-Ling, Lin, Ching-Yih, Sun, Ding-Ping, Sheu, Ming-Jen, Yang, Ching-Chieh, Lin, Li-Ching, He, Hong-Lin, Tian, Yu-Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604207/ https://www.ncbi.nlm.nih.gov/pubmed/28928864 http://dx.doi.org/10.7150/jca.19545 |
Ejemplares similares
-
High Expression of Aldolase B Confers a Poor Prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy
por: Tian, Yu-Feng, et al.
Publicado: (2017) -
PCSK1 Overexpression in Rectal Cancer Correlates with Poor Response to Preoperative Chemoradiotherapy and Prognosis
por: Chou, Chia-Lin, et al.
Publicado: (2020) -
Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy
por: Lee, Yi-Ying, et al.
Publicado: (2017) -
Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery
por: Yang, Kai-Lin, et al.
Publicado: (2013) -
Histopathological and Haemogram Features Correlate with Prognosis in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation without Pathological Complete Response
por: Huang, Yu-Ming, et al.
Publicado: (2022)